Pharma Focus Asia

FDA Staff backs Acadia's drug to treat psychosis associated with Parkinson's disease

Saturday, March 26, 2016

U.S. Food and Drug Administration staff members said on Friday Acadia Pharmaceuticals Inc's drug to treat psychosis associated with Parkinson's disease was effective enough to warrant approval.

The drug, Nuplazid, is a new chemical compound and could be the first drug specifically approved in the United States for Parkinson's disease psychosis (PDP).

 

Source : reuters.com

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024